Highlights Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Market Closed - Nasdaq Other stock markets 02:00:01 16/05/2024 am IST			5-day change	1st Jan Change
6.65 ^USD	0.00%		-5.67%	-10.14%

24/04	Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	CI
29/03	Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	24/04	CI
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004	13/02	CI
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	08/01	CI
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients	03/01	MT
Pasithea Therapeutics Gets FDA Acceptance for PAS-004 IND Application	02/01	DJ
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients	02/01	CI
Pasithea Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate	09/11	CI
Tranche Update on Pasithea Therapeutics Corp.'s Equity Buyback Plan announced on July 20, 2023.	14/23/14	CI
Pasithea Therapeutics Corp.'s Equity Buyback announced on July 20, 2023 has expired with 5,323,451 shares, representing 20.36% for $3.73 million.	08/23/08	CI
Pasithea Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
Pasithea Therapeutics Corp. announces an Equity Buyback for 5,714,285 shares, for $4 million.	09/23/09	CI
Pasithea Therapeutics Corp. authorizes a Buyback Plan.	09/23/09	CI
Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program	01/23/01	CI
Pasithea Therapeutics' Board Authorizes Share Repurchase Program Through $4 Million Tender Offer; Shares Rise	20/23/20	MT
Pasithea Therapeutics Corp. announces an Equity Buyback for 5,714,285 shares, representing 21.86% for $4 million.	20/23/20	CI
Pasithea Therapeutics Corp. authorizes a Buyback Plan.	20/23/20	CI
Lucy Scientific Discovery Inc. cancelled the acquisition of Pasithea Therapeutics Corp..	20/23/20	CI
Lucy Scientific Discovery Reiterates Proposal to Acquire Pasithea Therapeutics	30/23/30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Highlights

Filters